Tower Research Capital (TRC)’s Carisma Therapeutics CARM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-7,827
| Closed | -$3.28K | – | 5248 |
|
|
2024
Q4 | $3.28K | Buy |
7,827
+3,303
| +73% | +$2.72K | ﹤0.01% | 4677 |
|
|
2024
Q3 | $4.44K | Sell |
4,524
-11,563
| -72% | -$12.5K | ﹤0.01% | 4539 |
|
|
2024
Q2 | $24.5K | Buy |
16,087
+5,800
| +56% | +$8.65K | ﹤0.01% | 3643 |
|
|
2024
Q1 | $23.4K | Buy |
10,287
+5,670
| +123% | +$13.6K | ﹤0.01% | 2864 |
|
|
2023
Q4 | $13.5K | Sell |
4,617
-6,365
| -58% | -$18.9K | ﹤0.01% | 3955 |
|
|
2023
Q3 | $46.5K | Buy |
10,982
+9,252
| +535% | +$58.6K | ﹤0.01% | 2610 |
|
|
2023
Q2 | $15.2K | Buy |
1,730
+1,389
| +407% | +$7.56K | ﹤0.01% | 3644 |
|
|
2023
Q1 | $1K | Buy |
341
+134
| +65% | +$1.28K | ﹤0.01% | 5506 |
|
|
2022
Q4 | $3K | Sell |
207
-174
| -46% | -$1.83K | ﹤0.01% | 5157 |
|
|
2022
Q3 | $3K | Sell |
381
-208
| -35% | -$2.83K | ﹤0.01% | 5371 |
|
|
2022
Q2 | $10K | Sell |
589
-314
| -35% | -$3.59K | ﹤0.01% | 4433 |
|
|
2022
Q1 | $11K | Buy |
903
+242
| +37% | +$3.38K | ﹤0.01% | 4149 |
|
|
2021
Q4 | $11K | Buy |
661
+18
| +3% | +$362 | ﹤0.01% | 4391 |
|
|
2021
Q3 | $10K | Buy |
643
+330
| +105% | +$15.8K | ﹤0.01% | 4304 |
|
|
2021
Q2 | $29K | Sell |
313
-1,181
| -79% | -$75.3K | ﹤0.01% | 3515 |
|
|
2021
Q1 | $78K | Buy |
1,494
+903
| +153% | +$42.6K | ﹤0.01% | 2777 |
|
|
2020
Q4 | $16K | Sell |
591
-499
| -46% | -$12.7K | ﹤0.01% | 3999 |
|
|
2020
Q3 | $31K | Sell |
1,090
-790
| -42% | -$15.8K | ﹤0.01% | 3713 |
|
|
2020
Q2 | $27K | Buy |
1,880
+1,441
| +328% | +$19.4K | ﹤0.01% | 3503 |
|
|
2020
Q1 | $5K | Buy |
439
+279
| +174% | +$4.57K | ﹤0.01% | 2282 |
|
|
2019
Q4 | $3K | Sell |
160
-13
| -8% | -$299 | ﹤0.01% | 2880 |
|
|
2019
Q3 | $4K | Sell |
173
-29
| -14% | -$679 | ﹤0.01% | 3392 |
|
|
2019
Q2 | $7K | Buy |
+202
| New | +$6.05K | ﹤0.01% | 2751 |
|
|
2019
Q1 | – | Sell |
-13
| Closed | – | – | 3812 |
|
|
2018
Q4 | $0 | Buy |
+13
| New | +$415 | ﹤0.01% | 3844 |
|
|
2016
Q1 | – | Sell |
-22
| Closed | -$1K | – | 4160 |
|
|
2015
Q4 | $1K | Buy |
+22
| New | +$1.25K | ﹤0.01% | 4030 |
|
|
2015
Q2 | – | Sell |
-141
| Closed | -$25K | – | 4418 |
|
|
2015
Q1 | $25K | Buy |
+141
| New | +$30.8K | ﹤0.01% | 2062 |
|
|
2014
Q4 | – | Sell |
-496
| Closed | -$111K | – | 4052 |
|
|
2014
Q3 | $111K | Buy |
496
+453
| +1,053% | +$108K | 0.01% | 838 |
|
|
2014
Q2 | $11K | Buy |
+43
| New | +$10.6K | ﹤0.01% | 2262 |
|
Other funds holding CARM
MC
AIIC
Tower Research Capital (TRC)'s CARM Position: Q1 2025 in Review
Tower Research Capital (TRC) sold out of Carisma Therapeutics (CARM) in Q1 2025, closing a stake of 7,827 shares — an estimated $3.28K sold.
Tower Research Capital (TRC) first reported a position in CARM in Q2 2014 and held it in 28 quarters. The position peaked at $111K in Q3 2014. 37 funds tracked by Wall St. Rank hold CARM as of Q1 2025.
- Tower Research Capital (TRC) reported no remaining Carisma Therapeutics position as of Q1 2025 after selling out during the quarter.
- Tower Research Capital (TRC) sold 7,827 Carisma Therapeutics shares in Q1 2025, an estimated $3.28K.
- Tower Research Capital (TRC) first reported a position in Carisma Therapeutics in Q2 2014 and held it in 28 quarters.
- Tower Research Capital (TRC)'s Carisma Therapeutics position peaked at $111K in Q3 2014.
- 37 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q1 2025.
Based on Tower Research Capital (TRC)'s 13F filing for Q1 2025, filed 15 May 2025.